Peer reviewed
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)
Head-to-head trial showing tirzepatide superior to semaglutide for A1C reduction in Type 2 diabetes.
New England Journal of MedicinePublished 2021-08-05Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-tirzepatide-surpass2-2021
Source usage
Linked from 3 pages
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.